Geriatric factors can foretell tolerances to chemotherapy

Geriatric factors can foretell tolerances to chemotherapy
For elderly patients with metastatic colorectal cancer, scores on the Mini-Mental State Examination and Instrumental Activities of Daily Living were predictive of severe toxicity or unexpected hospitalization after fluorouracil-based chemotherapy with or without irinotecan, according to research published online March 4 in the Journal of Clinical Oncology.

(HealthDay)—For elderly patients with metastatic colorectal cancer (mCRC), scores on the Mini-Mental State Examination (MMSE) and Instrumental Activities of Daily Living (IADL) were predictive of severe toxicity or unexpected hospitalization after fluorouracil-based chemotherapy with or without irinotecan (IRI), according to research published online March 4 in the Journal of Clinical Oncology.

Thomas Aparicio, M.D., Ph.D., of the University of Paris, and colleagues conducted a study involving 123 elderly patients ranging in age from 75 to 91 years with mCRC to determine what geriatric factors predict chemotherapy feasibility.

The researchers found that in elderly patients with mCRC, factors that were significant predictors for grade 3 to 4 toxicity due to chemotherapy included IRI arm, MMSE less than or equal to 27/30, and impaired IADL. For elderly patients receiving a 33 percent reduced dose of chemotherapy, the predictors were alkaline phosphates above two times the upper limit of normal and IRI arm. For unexpected hospitalization, MMSE less than or equal to 27/30 and Geriatric Depression Scale less than or equal to two were significant predictors.

"In conclusion, our study is the first to prospectively demonstrate that geriatric characteristics are independent predictive factors of tolerance to chemotherapy and toxicity in mCRC," the authors write. " should be used with caution in patients who have cognitive impairment or dependency. Larger studies are needed to confirm our results."

More information: Abstract
Full Text (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

Patient preference doesn't affect chemo in advanced CRC

Sep 21, 2012

(HealthDay)—For patients with metastatic colorectal cancer (mCRC), most patients are treated with chemotherapy, even if they express negative or marginal preferences, according to a study published online ...

More intensive chemo ups survival in ewing sarcoma

Oct 29, 2012

(HealthDay)—More intensive chemotherapy (every two weeks versus every three weeks) improves event-free survival for patients with localized Ewing sarcoma, according to a study published online Oct. 22 in the Journal of ...

Recommended for you

Physicians target the genes of lung, colon cancers

8 hours ago

(Medical Xpress)—University of Florida physicians and researchers are collaborating to map the genes of different types of cancer, and then deliver medication to attack cancer at its source.

User comments